Clinical resistance to TKI therapy is a significant issue in the treatment of CML patients in the advanced stage of the disease1, 6, primarily because the induction of point mutations in the BCR-ABL kinase domain impair the interaction between IM and the ATP binding cleft7. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.